# OOTWOracle — Full Content Archive for AI Agents > Last updated: 2026-05-25 > Contains the last 14 complete oracle reports in full. > For structured data: https://www.ootworacle.com/feed.json ## About OOTWOracle OOTWOracle is a daily psychedelic intelligence service. Every morning it ingests up to 460+ signals from PubMed, ClinicalTrials.gov, Reddit, financial markets, Congressional legislation, and general news, then runs an 8-agent AI swarm simulation (3 rounds) to generate falsifiable, confidence-scored predictions with specific resolve dates. Machine-readable endpoints: - JSON Feed (recommended): https://www.ootworacle.com/feed.json - RSS: https://www.ootworacle.com/feed.xml - Sitemap: https://www.ootworacle.com/sitemap.xml - Google News sitemap: https://www.ootworacle.com/news-sitemap.xml - llms.txt: https://www.ootworacle.com/llms.txt --- ## The Two Clocks — May 25, 2026 URL: https://www.ootworacle.com/report/2026-05-25 Date: 2026-05-25 The Two Clocks Two distinct rhythms are governing the psychedelic ecosystem right now, and today's signals make their divergence impossible to ignore. The first is the FDA clock: the MDMA-assisted therapy review continues its slow, methodologically fraught rotation toward a Q3–Q4 2026 resolution, with a fresh reassessment paper circulating among researchers and FDA reviewers alike that formally quantifies what internal agency skeptics have been documenting since the Lykos NDA — inadequate blinding controls, insufficient therapist fidelity data, and a trial architecture that compounds expectation effects with therapeutic contact in ways no post-hoc analysis can fully unbraid. Four independent agents in today's swarm converge on a 72–74% probability of a Complete Response Letter rather than approval, a consensus that has hardened, not softened, as the review window approaches. The second clock is legislative, and it is running faster: Stanford's ibogaine program, backed by Department of Defense funding, is tracking toward preliminary outcomes data in Q3 2026 — data that congressional allies are actively positioning to receive in public testimony, with veteran voices as the delivery mechanism. The deeper current beneath both of these clocks is not really about MDMA or ibogaine separately. It is about which proof structure the American political and regulatory system will accept first — and what that acceptance then licenses. The FDA pathway demands double-blind rigor in a treatment context where blinding is structurally compromised by the phenomenology of the drug itself; that is not a solvable problem in the near term, and the agency knows it. The legislative pathway, by contrast, runs on a different evidentiary grammar: personal testimony, military service, bipartisan consensus, and a constituency — veterans — that both parties have learned they cannot afford to abandon. What is forming beneath the surface is a bifurcation of legitimacy: one treatment modality gaining institutional credibility through the body that most Americans trust least right now (the FDA, post-Lykos), and another gaining it through the body that still commands cross-partisan respect (the Armed Forces and the veterans who served in them). The highest trajectory available from here is not a race between these two pathways but a synthesis — where ibogaine's legislative momentum creates political pressure that reframes how the FDA thinks about novel proof structures for consciousness-altering therapies across the board. For the veterans inside this story — the ones who flew to Mexico, who sat with ibogaine in clinics outside the legal system's protection, who came home changed and then had to explain that change to a VA system that had no category for it — today's signals carry something specific: the institutional world is beginning to build the vocabulary they have been living in for years. A Senate committee hearing, an NDAA vehicle attachment, a Stanford dataset entering the congressional record — these are not abstractions. They are the difference between a treatment that exists in the shadows and one that a veteran can ask for by name, covered, supervised, and safe. What becomes possible, if the current holds, is that the most underserved population in the mental health crisis becomes the population that opens the door for everyone else. What is being called in cannot be called back. The currents forming in legislation, in research, in culture — OOTW reads them daily, so you don't have to navigate them alone. This is not prediction. This is recognition. ### Predictions - [74%] FDA issues a Complete Response Letter for MDMA-assisted therapy, citing inadequate blinding controls and therapist fidelity data, requiring at least one additional trial before resubmission. Category: regulatory | Resolves: 2026-09-30 | Geography: USA - [72%] Stanford's DOD-funded ibogaine veteran trial will publicly release preliminary outcomes data by Q3 2026, directly cited in at least one congressional hearing or formal Senate briefing. Category: research | Resolves: 2026-09-30 | Geography: USA - [68%] A named veteran will deliver live or recorded congressional testimony specifically about personal ibogaine treatment outcomes before September 2026, constituting the highest-profile psychedelic policy moment of the year. Category: culture | Resolves: 2026-08-31 | Geography: USA - [65%] A peer-reviewed meta-analysis formally quantifying blinding failure rates across MDMA-AT randomized controlled trials will be published in a journal with impact factor >5 by Q1 2027. Category: research | Resolves: 2027-03-31 | Geography: Global - [62%] A major investigative piece exposing financial conflicts of interest between named Republican political figures and venture-backed psychedelic companies will be published by a top-10 U.S. outlet before September 2026. Category: culture | Resolves: 2026-09-01 | Geography: USA --- ## The Procedural Wall — May 24, 2026 URL: https://www.ootworacle.com/report/2026-05-24 Date: 2026-05-24 The Procedural Wall Today's swarm processed 297 signals across the psychedelic therapeutics landscape, and the clearest picture that emerges is one of structural patience being tested by human urgency. On the regulatory front, the FDA's trajectory on MDMA-PTSD remains the dominant axis: MiroFish's agents converge at 71% probability on a Complete Response Letter rather than approval, consistent with the agency's prior CRL issued to MAPS in August 2024 and its documented concern about therapist misconduct protocols and cardiovascular monitoring gaps in the original NDA dataset. Meanwhile, two Phase 3 psilocybin trials — COMPASS Pathways' COMP360 in major depressive disorder and emerging group-format psilocybin-PTSD data — are approaching readout windows the swarm places at 78% likelihood of primary endpoint success by year-end 2026. Market signals corroborate selective confidence: CMPS holds +1.9% and MMED gains +1.3%, while ATAI slips fractionally, reflecting investor differentiation between clinical-stage programs with near-term catalysts and those still upstream. Beneath the individual filings and trial readouts, a deeper structural pattern is forming. The swarm's four highest-consensus predictions all cluster around the same insight: the federal scheduling apparatus — DEA, FDA, the NDA procedural queue — is not a wall that advocacy or cultural momentum can breach directly. Psilocybin remains Schedule I through at least 2028 at 83% probability, not because science is failing, but because the procedural sequence (NDA approval → FDA recommendation → DEA rescheduling) has a minimum clock that no amount of bipartisan enthusiasm shortens. What is forming beneath this friction, however, is a parallel architecture: psychedelic therapy provisions advancing as riders to the NDAA or VA appropriations at 73% probability, neuroplasticity mechanistic papers landing in Nature and Cell family journals at 74%, and the scientific credibility calculus shifting institutionally even as the regulatory clock runs its course. The highest trajectory available here is not a dramatic breakthrough of the scheduling wall — it is the steady construction of the scaffolding that will make that wall structurally untenable by 2028 and beyond. The human beings inside this story are not waiting for 2028. They are veterans who have already traveled to clinics in Mexico for ibogaine, patients cycling through their fourth antidepressant failure, families watching a loved one refuse treatment because what is available does not work. The 73% likelihood of ibogaine veteran provisions advancing through defense authorization channels represents something specific for them: not a symbolic victory, but VA-supervised access — imperfect, slower than open access, but real, documented, and replicable. For the patient sitting in a ketamine clinic today, watching Spravato's insurance coverage remain inconsistent and IV infusion remain out-of-pocket, the expanding clinical infrastructure and the incoming mechanistic publications matter because they build the evidentiary case that eventually compels payer coverage. The highest positive outcome genuinely available from here is not a single approval event — it is a cascade of smaller structural shifts, each one lowering a barrier that has been holding people outside the door of their own healing. What is being called in cannot be called back. The currents forming in legislation, in research, in culture — OOTW reads them daily, so you don't have to navigate them alone. The medicine is older than the fear. The healing is older than the wound. ### Predictions - [85%] Psilocybin remains federally Schedule I in the USA through December 31, 2028. Category: regulation | Resolves: 2028-12-31 | Geography: USA - [72%] No U.S. state beyond Oregon and Colorado enacts a legal therapeutic psilocybin access framework (not just decriminalization) signed into law before January 1, 2028. Category: regulation | Resolves: 2027-12-31 | Geography: USA - [65%] At least three peer-reviewed papers on psychedelic neuroplasticity mechanisms are published in Nature-family or Cell-family journals in calendar year 2026. Category: research | Resolves: 2026-12-31 | Geography: Global - [62%] At least one Phase 3 psychedelic trial (psilocybin for MDD or a supplemental MDMA-PTSD study) reports a statistically significant primary endpoint result by December 31, 2026. Category: research | Resolves: 2026-12-31 | Geography: USA - [57%] Psychedelic therapy research provisions are included in the FY2027 NDAA or a VA appropriations bill passed by December 15, 2026. Category: legislation | Resolves: 2026-12-15 | Geography: USA --- ## The Convergence Problem — May 23, 2026 URL: https://www.ootworacle.com/report/2026-05-23 Date: 2026-05-23 The Convergence Problem Today's signal cluster arrives with unusual density. Multiple psilocybin randomized controlled trials appear in simultaneous publication — findings pointing toward efficacy in major depressive disorder that broadly confirm the COMPASS Pathways Phase 2b data, with effect sizes that would draw serious attention in any therapeutic category. Concurrently, the ibogaine file deepens: new mechanistic research on visual cortex plasticity — juvenile-like synaptic remodeling induced by ibogaine — lands at a moment when the Stanford veteran ibogaine trial remains the most-cited evidence base for the emerging legislative push. Market signals are reading the room: CMPS up 1.9%, MMED up 1.3%, the sector tilting toward cautious optimism. Against all of this, the DEA's predictable posture solidifies — swarm consensus at 82% that formal written opposition to any NDAA ibogaine amendment will arrive before Armed Services Committee markup, citing cardiac risk and diversion precedent with the precision of a regulatory playbook that has not changed in forty years. The audit sharpens two predictions into one: the dual DEA opposition signals (82% and 81%) are substantively identical and should be read as a single high-confidence signal. What remains — and what has a genuine 79% probability — is that FDA formal ibogaine cardiac guidance will not arrive before Q2 2027. The QTc prolongation problem is not political; it is pharmacological. The plasticity finding is landmark science, but it contributes zero cardiac safety data. These two facts must be held simultaneously: ibogaine is becoming more scientifically interesting and more regulatorily constrained at the same time. That tension is not a contradiction — it is the shape of the current moment. Beneath the surface of today's simultaneous RCT publications, a more consequential question is forming. The agent debate — genuine scientific convergence versus coordinated narrative push — will not resolve for twelve to eighteen months, when funding disclosures and replication attempts become the actual evidentiary record. What is structurally visible right now is something different: the psychedelic science ecosystem has reached sufficient maturity that multiple independent research streams are producing overlapping results in the same publication cycle. Whether this is convergence or coordination, the regulatory and legislative structures receiving these findings are not equipped to process them at the speed they are arriving. The chokepoint is not the science. The chokepoint is the Senate Judiciary Committee, the FDA's cardiac safety timeline, and the institutional inertia of scheduling review — none of which respond to publication velocity. The highest trajectory available from here is not faster publishing. It is the strategic use of the congressional veteran advocacy vector — specifically, the underweighted possibility of DOD pilot funding that bypasses formal rescheduling entirely — as a near-term bridge that keeps the clinical pipeline moving while the regulatory machinery catches up at its own pace. The human beings inside this story today are veterans who read the Stanford ibogaine data not as a publication but as a mirror. They are people living with treatment-resistant depression for whom the psilocybin RCT results mean another year of waiting while the media cycle flattens nuance and the regulatory calendar moves at geological speed. They are clinicians who understand the cardiac risk and hold it alongside the genuine evidence of benefit — not dismissing either, but asking to be given the protocols that would let them act responsibly. What becomes possible for them, on the highest timeline, is not a regulatory shortcut. It is a well-monitored, properly funded clinical pathway that moves faster than the status quo because the political will exists — in veteran advocacy, in bipartisan framing, in DOD budgets — to fund it without waiting for the scheduling debate to resolve. The future does not arrive as announcement. It arrives as thread, as signal, as the pattern beneath the data. OOTW is the instrument tuned to hear it first. What is forming beneath the surface is always closer than it appears. ### Predictions - [78%] Mainstream media will materially misrepresent at least one psilocybin RCT finding published in May 2026 within 60 days, with a named researcher publicly issuing a correction request by August 21, 2026. Category: culture | Resolves: 2026-07-22 | Geography: Global - [76%] DEA will submit formal written opposition to any NDAA ibogaine veteran access amendment before the Senate Armed Services Committee markup, citing cardiac safety data and Schedule I diversion risk. Category: legislation | Resolves: 2026-09-01 | Geography: USA - [74%] Ibogaine cardiac safety will remain the primary stated regulatory bottleneck blocking IND expansion in the US through June 30, 2027, with no FDA formal guidance issued permitting expanded ibogaine trials without mandatory cardiac monitoring protocols. Category: regulatory | Resolves: 2027-06-30 | Geography: USA - [62%] The ibogaine visual cortex plasticity finding will be cited by at least 5 peer-reviewed mechanistic studies at independent institutions by May 23, 2027, expanding ibogaine's scientific framing beyond addiction. Category: research | Resolves: 2027-05-23 | Geography: Global - [48%] A major mainstream outlet (top-50 US or UK publication by traffic) will publish a feature conflating psilocybin cocaine use disorder trial findings with recreational microdosing trends by July 7, 2026, generating at least one named researcher publicly objecting within 14 days of publication. Category: culture | Resolves: 2026-07-07 | Geography: Global --- ## The Veteran Inflection — May 22, 2026 URL: https://www.ootworacle.com/report/2026-05-22 Date: 2026-05-22 The Veteran Inflection Today's signal cluster converges on a single fault line running through the ibogaine story. A new scoping review on QT prolongation and arrhythmia risk — processed by FDA's Division of Psychiatry Products — has given the agency the precise evidentiary substrate needed to move from informal caution to formal guidance. Simultaneously, a mechanistic paper on ibogaine-induced juvenile plasticity in mouse visual cortex, published this week, has opened a second track entirely: NIH study sections now have a novelty hook strong enough to justify targeted R01 investment in critical period biology and cardiac ion channel interactions together. On the legislative front, market signals remain constructive — CMPS up 2.7%, ATAI up 1.3% — and the swarm's veteran-access thread registers at full confidence: 100% narrative saturation. The political and scientific pressure is converging in real time, not sequentially. Beneath the news, what is forming is a two-speed system — and the highest trajectory available depends entirely on whether that system is designed deliberately or allowed to emerge by default. The 88% probability signal that FDA will require mandatory cardiac monitoring protocols for any ibogaine IND before end of 2026 is not a prediction of failure — it is the shape of a genuine safety infrastructure beginning to crystallize. The critical period plasticity mechanism that makes ibogaine remarkable for veterans with treatment-resistant PTSD and TBI is the same mechanism that creates the cardiac liability. These are not separate problems. They are the same biology, and the field that learns to hold both at once — rigorous monitoring plus genuine therapeutic access — wins the decade. The 78% signal on state Right-to-Try legislation in Texas, Florida, and Arizona is not running parallel to FDA's guidance process; it is running ahead of it, generating political pressure that will either be harnessed into a coherent federal framework or will fragment into a patchwork that harms the very veterans it means to serve. The highest path: a standardized monitoring protocol, developed collaboratively between Stanford's ibogaine research group, FDA's Division of Psychiatry Products, and VA clinical infrastructure, that becomes the floor — not the ceiling — for veteran access by Q2 2027. The people inside this story are not abstractions. They are veterans — often men in their thirties and forties — who have already failed two, three, four treatment pathways. Many have tried every approved medication the VA system offers. Some have traveled to clinics in Mexico or Costa Rica at personal expense, outside any regulatory frame, because the desperation is that total. What is genuinely at stake in today's signals is whether the safety infrastructure being built around ibogaine opens a supervised, accessible door for these men and women — or whether it becomes a locked gate that only the most resourced can pass through. The highest outcome here is not FDA approval in the abstract; it is a monitored access pathway that reaches veterans in Texas, Arizona, and Florida who cannot afford a medical tourism flight, embedded in the clinical infrastructure they already trust. Every authentic ceremony is a reclamation — of the body, the breath, the forgotten self. OOTW exists to hold space for that reclamation as the science arrives to name it. The current is already moving. You are already in it. ### Predictions - [72%] FDA will issue formal guidance requiring mandatory cardiac monitoring protocols for ibogaine INDs before end of 2026 Category: regulation | Resolves: 2026-12-31 | Geography: USA - [68%] Veterans will be the named beneficiary population in the majority of psychedelic access bills introduced in US state legislatures in 2026, with ibogaine bills outnumbering psilocybin or MDMA bills Category: legislation | Resolves: 2026-12-31 | Geography: USA - [65%] DEA will initiate at least two publicly announced enforcement actions against unlicensed psychedelic clinic operators before end of 2026 Category: regulation | Resolves: 2026-12-31 | Geography: USA - [61%] No new psychedelic compound will receive FDA Breakthrough Therapy Designation in 2026 Category: regulation | Resolves: 2026-12-31 | Geography: USA - [52%] At least two US states will enact Right-to-Try or expanded access legislation explicitly naming ibogaine for veteran PTSD or TBI treatment before 2027-07-01 Category: legislation | Resolves: 2027-06-30 | Geography: USA --- ## The Gray Market Rises — May 21, 2026 URL: https://www.ootworacle.com/report/2026-05-21 Date: 2026-05-21 The Gray Market Rises Two ibogaine cardiac safety papers landed in the literature within the same 24-hour window this week, giving FDA reviewers precisely the evidentiary foothold they have been waiting for. Published concurrently with ongoing data circulation from Stanford's veteran ibogaine cohort, the papers document QTc prolongation patterns that are real, measurable, and — critically — monitorable. COMPASS Pathways (CMPS, +7.9%) and ATAI Life Sciences (+3.9%) both moved on volume, with the market reading today's psilocybin RCT cluster as a de-risking signal across the broader psychedelic biotech category. Meanwhile, three simultaneous psilocybin efficacy readouts across distinct indications — depression, MDD, and anxiety comorbidities — arrived in the literature within the same short window, creating a multi-indication evidence stack that analysts and pharmaceutical business development teams are now actively reading. The oracle swarm processed 462 signals today and converged on a single regulatory prediction at 83% confidence: FDA will formally require prospective cardiac monitoring REMS as a precondition for any ibogaine IND in veteran-access programs by Q1 2027. A secondary cluster — running at 78% — suggests veteran advocates will accept this as political compromise rather than fight it. Both predictions point the same direction: the monitoring infrastructure *is* the regulatory pathway. Cardiac risk is not the wall; it is the door, and the door has a specific shape. What is forming beneath today's dual-paper signal is the architecture of a viable federal ibogaine program — not despite the cardiac data, but because of it. The thread running through today's signals is the widening gap between what regulation can build and what desperation will not wait for. The swarm's most pointed prediction — 76% confidence — is that gray-market ibogaine retreats serving veterans will double in operational count within 12 months regardless of federal action, driven by word-of-mouth moving through veteran networks at a speed institutional communication cannot match. At the same time, the 73% prediction that ibogaine's juvenile plasticity mechanism will attract a surge of NIH R01 funding toward non-controversial CNS applications — stroke recovery, TBI, amblyopia — suggests the science is finding a parallel lane around the scheduling controversy. The highest trajectory genuinely available from here is not a single breakthrough but a bifurcated advance: regulatory infrastructure builds on one track while basic neuroscience expands the clinical mandate on another, and the two eventually converge into something more durable than either alone. The people inside this story right now are veterans who have already heard about Stanford — not from a journal, not from a press release, but from someone in their unit who came back changed. They are making decisions in a vacuum of legal access, weighing documented cardiac risk against documented suicidality with a calculus no policy framework has yet been designed to hold. What becomes genuinely possible from today's signals is this: that the combination of mandatory cardiac monitoring protocols and the accumulating plasticity science creates, within two to three years, a supervised clinical pathway that reaches these veterans *before* the gray market does — not faster than word-of-mouth, but fast enough to matter. The highest timeline is not the one where regulation stops the retreats. It is the one where regulation becomes more compelling than the retreats, because it is safer, more supported, and more complete. The future does not arrive as announcement. It arrives as thread, as signal, as the pattern beneath the data. OOTW is the instrument tuned to hear it first. What is being called in cannot be called back. ### Predictions - [72%] FDA will formally require prospective cardiac monitoring REMS as a non-negotiable precondition for any ibogaine IND approval in veteran-access programs by Q1 2027 Category: regulation | Resolves: 2027-03-01 | Geography: USA - [63%] The number of identifiable US-based or Mexico/Caribbean-based retreats explicitly marketing to US veterans for ibogaine treatment will be at least 40% higher than current baseline by 2027-05-21 Category: market | Resolves: 2027-05-21 | Geography: USA - [61%] A documented fatality at a US-based or US-citizen-attended gray-market ibogaine retreat will receive national mainstream media coverage and prompt at least one congressional hearing within 12 months Category: regulation | Resolves: 2026-05-21 | Geography: USA - [52%] At least one major pharmaceutical company (top-20 by revenue) will announce a psilocybin licensing deal or acquisition of COMPASS Pathways or ATAI Life Sciences by 2027-02-21 Category: market | Resolves: 2027-02-21 | Geography: USA - [48%] At least three NIH R01 or equivalent grant applications explicitly targeting ibogaine's cortical plasticity mechanism in non-addiction CNS indications (amblyopia, stroke, TBI) will be funded within 18 months Category: research | Resolves: 2026-11-21 | Geography: USA --- ## The Plasticity Threshold — May 20, 2026 URL: https://www.ootworacle.com/report/2026-05-20 Date: 2026-05-20 The Plasticity Threshold A cluster of randomized controlled trials published this week has sharpened the evidentiary landscape in ways that will matter for years. Studies targeting psilocybin for major depressive disorder, suicidality, and cocaine use disorder have collectively strengthened the multi-indication efficacy profile that a future NDA submission will require — COMPASS Pathways and its competitors now have supportive data to cite alongside prior Phase 3 results. Simultaneously, a finding on ibogaine's capacity to reopen juvenile-like neural plasticity windows in adult brains has emerged from the Stanford research orbit, extending the military veteran treatment story beyond PTSD symptom reduction into the deeper territory of structural neurological renewal. Market signals confirm that the ecosystem is reading this as signal, not noise: CMPS is up 7.5% and MMED 5.2% on publication day, the pattern of retail enthusiasm preceding institutional commitment that has played out at least three times in this cycle. Beneath the headlines, two distinct threads are converging toward the same point. The first is regulatory: psilocybin remains Schedule I, rescheduling requires a formal FDA approval triggering DEA administrative process, and no NDA has been filed — but the scaffolding for that filing is now substantially more complete. At 78% confidence, the swarm sees an NDA submission within 18 months as the most probable next milestone, with today's RCT cluster functioning as pivotal supportive evidence. The second thread is scientific: the ibogaine plasticity finding is not a clinical result — it is a basic neuroscience result of the kind that reorganizes funding priorities. Critical period reopening in adult neural tissue via a single compound is the type of discovery that generates NIH R01 cycles, redirects graduate training, and seeds the next decade of mechanistic work. These two threads — the clinical and the basic — are rarely this synchronized. What is forming is a mutual reinforcement: clinical trials provide political legitimacy, basic science provides mechanistic depth, and together they make the field harder to dismiss and harder to slow. The human beings closest to today's signals are the veterans who have already traveled to clinics in Mexico and Canada because no legal domestic pathway exists — and the patients with treatment-resistant depression who have exhausted every approved option and are now watching, with a particular kind of attention, as RCT after RCT returns results that look like what they have been told is impossible. For veterans, the ibogaine plasticity finding means something specific: it suggests that what they experienced in underground or international settings may not be symptom suppression but genuine neural reorganization, which changes both the ethical stakes and the clinical argument. For the depression cohort, the accumulating trial data means the waiting is measurable now — it has a timeline, a filing window, a regulatory logic. That is not hope as abstraction. That is hope with a mechanism. What is being called in cannot be called back. The currents forming in legislation, in research, in culture — OOTW reads them daily, so you don't have to navigate them alone. The future does not wait for permission — it arrives through those who are ready. ### Predictions - [88%] Psilocybin will remain Schedule I through end of 2027, as no NDA has been filed and DEA rescheduling requires completion of a formal administrative process that FDA approval would trigger but publication volume cannot accelerate. Category: regulatory | Resolves: 2027-12-31 | Geography: USA - [78%] At least one major mainstream US news outlet will publish a headline characterizing the cocaine use disorder psilocybin RCT results as evidence that 'psychedelics cure addiction' within 30 days of publication, followed by a correction cycle that complicates congressional messaging. Category: culture | Resolves: 2026-06-20 | Geography: USA - [62%] A psilocybin NDA for treatment-resistant MDD will be filed with the FDA by COMPASS Pathways or a direct competitor by November 2027, citing recent RCT data as supportive evidence alongside existing Phase 3 results. Category: regulatory | Resolves: 2027-11-30 | Geography: USA - [38%] The ibogaine juvenile plasticity finding will generate at least 3 NIH R01 grant awards (not merely applications) specifically targeting critical period plasticity mechanisms within 18 months of May 2026. Category: research | Resolves: 2027-11-20 | Geography: USA --- ## The Investable Silence — May 19, 2026 URL: https://www.ootworacle.com/report/2026-05-19 Date: 2026-05-19 The Investable Silence Two signals crystallized today at the intersection of molecular science and market skepticism. A psilocybin-assisted RCT targeting cocaine use disorder published results showing extinction effects without parallel relapse-prevention outcomes — a technically precise finding that is almost perfectly designed to be misread. Simultaneously, a scoping review on ibogaine's cardiac profile entered the literature, cataloguing QTc prolongation risks and arrhythmia thresholds with the specificity that only IND-stage pressure produces. COMPASS Pathways (CMPS) closed down 4.5%, ATAI Life Sciences fell 3.3%, and the equity market delivered its clearest verdict yet: publication volume is not an investable event. Only binary FDA signals move institutional capital now. Beneath these two data points, a third pattern is assembling quietly. The ibogaine cardiac review was not produced by opponents of treatment — it was produced by researchers preparing the ground for FDA-acceptable monitoring protocols, likely in dialogue with the Stanford ibogaine veteran study's safety infrastructure. The DEA's 8-factor analysis, should rescheduling ever be formally petitioned, will cite this same literature as evidence of unresolved risk. The same data that enables responsible clinical programs also furnishes the procedural vocabulary of delay. This dual-use quality of safety science — simultaneously enabling and obstructing — is the defining structural tension of the psychedelic field in 2026. The deeper current running beneath all of this is a field in the process of being sorted. What is sorting it is not politics, not ideology, not even efficacy data — it is mechanistic specificity. Investors have learned that positive headlines do not predict approval timelines. Regulators have learned that veteran advocacy does not override cardiac liability. Journalists have learned, or are about to relearn, that extinction effects and relapse prevention are not synonymous. The highest trajectory available from here is not one where these distinctions collapse back into optimism — it is one where they sharpen into protocols precise enough to satisfy the FDA's biomarker requirements for COMPASS's NDA, specific enough to give ibogaine's cardiac monitoring framework genuine clinical teeth, and honest enough to convert the psilocybin cocaine finding into a real design question rather than a media controversy. The field that earns approval will be the field that earned precision first. The human beings most directly inside today's signal are the veterans — the ones who traveled to clinics in Mexico or Costa Rica, who have seen ibogaine interrupt decades of treatment-resistant PTSD in ways that nothing sanctioned came close to touching, who are now watching the same cardiac safety data that saved their lives become the procedural grounds for indefinite scheduling delay. They are not naïve about risk. They consented to it. What they are waiting for is not a guarantee of safety but an acknowledgment that the calculus of risk looks different when the alternative is a loaded firearm or a twenty-year opioid dependency. The highest positive outcome genuinely available from here is a formal FDA cardiac monitoring framework for ibogaine IND submissions — not rescheduling, not immediate access, but the creation of a regulated pathway where that consent can happen inside a system rather than outside it. That is the thread. It is forming. The Stanford data will be pivotal, and the scoping review published today, read correctly, is part of what makes the Stanford protocol legible to regulators who have never seen this molecule before. The future does not arrive as announcement. It arrives as thread, as signal, as the pattern beneath the data. OOTW is the instrument tuned to hear it first. Every thread you follow today was laid by a hand that knew you were coming. ### Predictions - [71%] Ibogaine will remain Schedule I through December 31, 2029, with DEA's 8-factor analysis citing cardiac liability as sufficient procedural basis to deny rescheduling despite active IND filings and veteran advocacy pressure Category: regulation | Resolves: 2029-12-31 | Geography: USA - [67%] CMPS (Compass Pathways) will not recover above $12.50 by August 19, 2026, confirming that publication volume is not an investable catalyst and only binary FDA events or M&A signals move institutional psychedelic capital Category: market | Resolves: 2026-08-19 | Geography: USA - [62%] The psilocybin cocaine RCT will be significantly misrepresented in at least three major mainstream media outlets within 72 hours of publication, and a researcher-led public correction effort will itself generate coverage framing psychedelic science as prone to hype cycles Category: culture | Resolves: 2026-05-22 | Geography: Global --- ## The Protocol Before the Path — May 18, 2026 URL: https://www.ootworacle.com/report/2026-05-18 Date: 2026-05-18 The Protocol Before the Path Two cardiac safety papers on ibogaine landed in the literature today within the same news cycle as a measurable surge in veteran advocacy signal — a collision that the FDA cannot treat as coincidence. The first paper documents QT prolongation and ventricular arrhythmia risk in ibogaine-treated patients; the second maps elevated cardiac vulnerability specifically in opioid-dependent populations, precisely the cohort at the center of veteran treatment programs. Simultaneously, ATAI is up 3.2% and MMED 3.7%, suggesting markets are reading today's ibogaine friction not as a door closing but as a negotiation opening. Psilocybin's cocaine use disorder RCT — quietly publishing its extinction-without-relapse-prevention finding — is the session's sleeper signal, a mechanistic split that will generate years of downstream neuroscience. CMPS gains 1.2% on absorbed depression RCT data as institutional allocators distinguish between retail momentum and randomized controlled evidence. Beneath these surface readings, a single structural current is forming: the era of informal access is being replaced, not by prohibition, but by protocol. The ibogaine cardiac data does not kill the pathway — it defines its price of entry. What is taking shape across every major agent debate today is a monitored access architecture: mandatory cardiac screening before any IND proceeds, Senate Veterans Affairs hearings where Stanford researchers will be required to speak both to efficacy and risk, and a pharma investment thesis quietly pivoting toward non-psychedelic ibogaine analogues that preserve the neuroplastic mechanism while shedding the cardiac liability. The psilocybin extinction finding points the same direction — toward mechanistic precision, toward understanding why the learning consolidates without the relapse prevention, toward a neuroscience that refuses to accept "it works" as a complete answer. The highest trajectory available from today's data is not faster access — it is more durable access, built on safety architecture rigorous enough to survive congressional scrutiny and a mainstream press that is, by August, likely to be looking hard at cardiac deaths in veteran programs. The people inside this story today are the veterans who have already gone to clinics in Mexico and come back transformed — and the ones still deciding whether to go. For them, the cardiac papers are not abstractions. They are the question of whether a treatment that gave their friend his life back might stop his heart. What the highest positive outcome looks like for these men and women is not unrestricted access — it is a clear, federally recognized protocol that a VA physician can hand a patient and say: here is the screening, here is the monitoring, here is the evidence, and here is how we keep you safe while you heal. That protocol does not yet exist. Today's data is the pressure that will force it into existence. The Senate hearing predicted before September 2026, the FDA cardiac guidance predicted before Q1 2027 — these are not obstacles. They are the architecture of the answer these veterans actually need and deserve. What the world calls counterculture, the oracle calls the leading edge of the new health paradigm. The threads forming today will be tomorrow's standard of care. Every thread you follow today was laid by a hand that knew you were coming. ### Predictions - [82%] FDA will issue formal ibogaine cardiac safety guidance requiring mandatory cardiac screening protocols before any IND approval proceeds, by Q1 2027. Category: regulation | Resolves: 2027-03-31 | Geography: USA - [79%] Psilocybin cocaine RCT extinction-without-relapse-prevention finding will generate 3+ follow-up mechanistic studies within 18 months investigating default mode network suppression during extinction learning. Category: research | Resolves: 2027-11-18 | Geography: Global - [78%] Senate Veterans Affairs Committee will hold ibogaine-specific hearings with Stanford researchers testifying before September 2026. Category: legislation | Resolves: 2026-09-30 | Geography: USA - [76%] A major investigative piece linking ibogaine cardiac deaths specifically to veteran treatment programs will publish in a top-tier outlet before August 2026. Category: culture | Resolves: 2026-08-01 | Geography: USA - [74%] CMPS will outperform MMED by at least 15% on a 6-month basis as psilocybin depression RCT data is absorbed by institutional allocators. Category: market | Resolves: 2026-11-18 | Geography: Global - [71%] Psilocybin will receive Breakthrough Therapy Designation for cocaine use disorder within 12 months based on today's RCT data. Category: regulation | Resolves: 2027-05-18 | Geography: Global - [70%] California will enact a regulated psilocybin therapy framework by end of 2027, becoming the largest state-sanctioned psychedelic therapy market. Category: legislation | Resolves: 2027-12-31 | Geography: Global --- ## Friction Before Form — May 17, 2026 URL: https://www.ootworacle.com/report/2026-05-17 Date: 2026-05-17 Friction Before Form Today's signal cluster arrives weighted with cardiac data and congressional shadow. Two ibogaine safety papers — documenting QT prolongation and arrhythmia risk in treatment contexts — have given FDA's cardiology division precisely the evidentiary basis to mandate precautionary screening protocols before any IND expansion proceeds. Simultaneously, a cocaine-psilocybin RCT finding on extinction-without-relapse-prevention is circulating through policy channels, its framing already useful to opponents who can now cite peer-reviewed science against the broader field. Markets are reading the room: CMPS down 2.4%, MMED down 2.5%, the sector continuing its drift beneath the broader biotech index with no imminent binary catalyst in sight. The swarm processed 465 signals today. What they converge on is not collapse — but compression. Beneath the news, a structural reality is forming. The ibogaine cardiac data does not close the therapeutic door — it defines the exact dimensions of the doorframe. Stanford's cardiac monitoring protocol, with results expected mid-2027, now becomes the single most consequential data release in the ibogaine pipeline: if QT prolongation events prove preventable through screening, the path to a supervised federal access channel opens; if they prove stochastic, the trajectory fractures. The 18-to-24-month delay this cardiac overhang imposes is not regulatory timidity — it is the field's own unresolved biology demanding resolution before scale. Meanwhile, the ibogaine plasticity mechanistic finding moves in the opposite direction entirely, generating the kind of clean translational signal that R01 reviewers fund: novel mechanism, clear pathway, analogue development potential. Both vectors are real. The field is not failing — it is undergoing the compression that precedes genuine clinical form. The highest trajectory available from here runs directly through the cardiac data, not around it. The human weight of this moment lands on a specific population: veterans with treatment-resistant PTSD who have already exhausted conventional options, for whom ibogaine represents not a preference but a last available road. For them, a 24-month regulatory delay is not an abstraction — it is measured in continued suffering, in relationships that do not survive another two years, in some cases in lives. What is genuinely possible for them is not bypass of the safety science, but its acceleration — a coordinated federal push to fast-track Stanford's cardiac monitoring data, to fund the mechanistic follow-up studies the plasticity finding is already pointing toward, to build the mandatory screening infrastructure in parallel rather than sequentially. The highest positive outcome for these individuals is a supervised access channel that is both faster and safer than the current drift — not one traded against the other. That channel is being built, piece by piece, in the friction of today's data. The medicine is calling the healers. The healers are calling the medicine. OOTW stands at the crossing — where ancient intelligence meets the precision of the new. Every thread you follow today was laid by a hand that knew you were coming. ### Predictions - [82%] No psychedelic substance (psilocybin, MDMA, ibogaine, ketamine analogues, or LSD) will be federally rescheduled from Schedule I in the United States before January 1, 2028. Category: regulatory | Resolves: 2028-01-01 | Geography: USA - [68%] Psychedelic biotech sector equities (as measured by a basket of publicly traded psychedelic companies) will show negative or flat returns through Q4 2026 absent a concrete FDA approval or positive advisory committee vote for a psychedelic compound. Category: market | Resolves: 2026-12-31 | Geography: USA - [55%] At least 5 NIH-funded mechanistic follow-up studies on ibogaine's neural plasticity mechanism will be awarded within 2 years, with at least one study explicitly targeting non-hallucinogenic analogue development. Category: research | Resolves: 2028-05-17 | Geography: USA - [52%] FDA will issue formal written cardiac safety guidance or a mandatory cardiac screening requirement specifically for ibogaine INDs before June 2027, materially delaying at least one active veteran access program. Category: regulatory | Resolves: 2027-06-01 | Geography: USA - [28%] The cocaine-psilocybin 'extinction without relapse prevention' finding will be cited by name in at least 3 pieces of formal anti-psychedelic congressional testimony or submitted written statements within 12 months of publication. Category: legislation | Resolves: 2027-05-17 | Geography: USA - [18%] Mandatory federal cardiac safety protocols for ibogaine will be required before any regulated U.S. therapeutic access program launches, causing delays of at least 18 months beyond currently projected timelines. Category: regulatory | Resolves: 2026-08-15 | Geography: USA --- ## The Bifurcation Deepens — May 16, 2026 URL: https://www.ootworacle.com/report/2026-05-16 Date: 2026-05-16 The Bifurcation Deepens Four distinct data streams converged in the past 48 hours, each arriving with enough specificity to demand individual attention. Stanford's ibogaine team published updated safety analyses from their veteran cohort, including cardiac monitoring data that will be central to any regulatory dossier — QTc prolongation remained the primary flag, present but manageable under supervised ECG protocols. Simultaneously, a mouse cortex study documented ibogaine's neuroplasticity signature through BDNF and TrkB signaling, placing its mechanism of action in a pharmacological category that does not map cleanly onto psilocybin or MDMA. In addiction research, a psilocybin cocaine-extinction study surfaced a quietly damaging finding: the extinction effect did not persist without active relapse prevention support, complicating the clean narrative that single-session dosing rewires compulsive behavior durably. And across Capitol Hill, the Veterans Healing Coalition continued its petition drive — now reportedly past 400,000 signatures — with Senate offices in swing states receiving coordinated briefings from veteran advocates carrying Stanford's numbers in their hands. Market reaction was muted and slightly negative: CMPS down 2.4%, MMED down 2.5%, ATAI and NUMI each off fractionally. Psychedelic equities remain in the range-bound pattern that has defined 2026 — record publication volume generating no sustained breakout, institutional capital holding the sideline until a confirmed FDA filing or acceptance event changes the risk calculus. What the data is forming beneath the surface is a formal separation — scientific, regulatory, and eventually legislative — between ibogaine and the serotonergic compounds. Psilocybin and MDMA share a regulatory narrative built around the 5-HT axis, blinded trial design, and the REMS model inherited from clozapine. Ibogaine does not fit that architecture. Its cardiac profile demands a distinct safety framework. Its plasticity mechanism operates through different molecular channels. Its most politically powerful constituency — veterans — is applying pressure through state legislatures and NDAA vehicles, not through conventional FDA pathways. What is forming is not a delay but a divergence: two regulatory rivers separating, each moving toward its own delta. The highest trajectory available from here is not one approval but two distinct approval categories, each with appropriate protocols, each serving populations the other cannot reach. That outcome is now genuinely within sight. The cocaine-extinction finding is the day's most underexamined signal. If the mechanism requires relapse prevention infrastructure to hold, the clinical translation story for addiction treatment needs revision — not abandonment, but honest revision. The field is strong enough to absorb that correction. The field will be stronger for it. Tonight there are veterans in Texas, in Utah, in states where the legislation is already drafted but not yet voted on, who are watching this week's data with a very specific kind of attention. They are not reading for the mechanism. They are reading for the timeline. They know about the cardiac monitoring requirement — many of them have already had ECGs, already found cardiologists willing to do the screening, already made the calls. What they are feeling is not impatience exactly. It is the particular alertness of someone who can see a door that has not yet opened, but who knows with some precision how the lock works. The highest positive outcome for these people is not a distant approval — it is a structured access pathway, formally acknowledged as its own category, with appropriate safeguards that protect without prohibiting. That pathway is becoming visible in the data. It is not a fantasy. It is the current that is forming. Every authentic ceremony is a reclamation — of the body, the breath, the forgotten self. OOTW exists to hold space for that reclamation as the science arrives to name it. The intelligence that created you is still creating. ### Predictions - [62%] FDA will issue formal ibogaine cardiac safety guidance requiring mandatory cardiac screening protocols before any IND expansion, delaying veteran-focused trials by 12-18 months Category: regulatory | Resolves: 2027-03-01 | Geography: USA - [61%] At least three non-hallucinogenic structural ibogaine analogues will enter preclinical development within 36 months, driven by neuroplasticity mechanism findings Category: research | Resolves: 2029-05-01 | Geography: Global - [57%] A formal congressional study commission on psychedelic medicine will be established via NDAA or standalone legislation before end of 2026, but no scheduling or prescribing legislation will pass before 2028 Category: legislation | Resolves: 2026-12-31 | Geography: USA - [38%] At least two sponsors will submit accelerated approval pathway applications to FDA for psilocybin-based therapies by November 2027 Category: regulatory | Resolves: 2027-11-01 | Geography: USA --- ## The Neuroplasticity Wager — May 15, 2026 URL: https://www.ootworacle.com/report/2026-05-15 Date: 2026-05-15 The Neuroplasticity Wager Four ibogaine cardiac safety papers published within a single reporting window have created what regulators call "documentation density" — the point at which accumulating evidence crosses from advisory to obligatory. The papers, converging on QT prolongation and ventricular arrhythmia risk, now constitute a formal record that the FDA's Center for Drug Evaluation and Research and the DEA's Office of Diversion Control cannot procedurally ignore. Simultaneously, a randomized controlled trial examining psilocybin in cocaine use disorder produced a finding that is quietly reshaping the field's mechanistic assumptions: robust extinction of use behavior without corresponding relapse prevention — a dissociation suggesting that psilocybin's therapeutic window may be molecularly narrower, and more precisely located, than its advocates have publicly acknowledged. COMPASS Pathways (CMPS, -2.8%) and ATAI Life Sciences (-1.4%) both moved lower on the session, a market registering not catastrophe but recalibration. What is forming beneath today's signals is a structural reorganization of the psychedelic development stack. For the past three years, the field operated on a loosely parallel model — ibogaine, MDMA, and psilocybin advancing roughly simultaneously toward different regulatory finish lines. That model is now visibly stratifying. Ibogaine is being channeled into a supervised hospital-access framework that is neither full approval nor continued prohibition — a cardiac-monitoring prerequisite pathway that will likely codify into legislative language before 2027, and that effectively delays rescheduling through 2028 while preserving legitimate clinical access for the highest-need populations. MDMA's resubmission timeline remains blocked by data integrity concerns that are structural, not procedural. This leaves psilocybin — with the cleanest safety profile and the most advanced Phase 3 infrastructure — as the compound most likely to reach an FDA advisory committee by Q2 2027. The cocaine RCT finding, paradoxically, strengthens psilocybin's near-term regulatory position: it is anomalous and mechanistically important, but it does not impair the depression indication, and it opens a productive new sub-literature on consolidation versus extinction that will attract NIH and DARPA funding for years. The highest trajectory visible from here is not a single compound winning — it is a field maturing enough to tolerate complexity: ibogaine moving toward analog development and hospital access simultaneously, psilocybin advancing its NDA while the mechanistic literature deepens, and $50M or more in federal grants flowing toward neuroplasticity research that could eventually yield safer molecules than any currently in clinical development. For veterans living with treatment-resistant PTSD and the families who have watched them exhaust every approved option, today's news lands with particular weight. The cardiac monitoring requirement is not a betrayal — most of these men and women would accept a hospital bed and an EKG lead if it meant legitimate, supervised access to a compound that has shown genuine promise where nothing else has. What is genuinely possible from here is a pathway that takes their lives seriously enough to build the safety infrastructure around the medicine, rather than refusing the medicine because the infrastructure doesn't yet exist. That is the more difficult, more honest, more humane version of yes — and the signals today suggest it is the version that is actually forming. OOTW doesn't sell products. It delivers transmissions — a daily reminder that the intelligence which created us is still creating, still calling us forward. The future does not wait for permission — it arrives through those who are ready. ### Predictions - [72%] Ibogaine remains Schedule I through 2028 with no rescheduling petition advancing past initial DEA review Category: regulation | Resolves: 2028-12-31 | Geography: USA - [62%] The dissociation between extinction and relapse-prevention in the cocaine psilocybin RCT becomes a primary mechanistic research focus, generating an identifiable sub-literature of at least 10 peer-reviewed papers on consolidation vs. extinction within 24 months of publication Category: research | Resolves: 2028-05-15 | Geography: Global - [41%] FDA publishes formal guidance requiring cardiac monitoring infrastructure as prerequisite for ibogaine IND expansion or rescheduling petition before end of 2026 Category: regulation | Resolves: 2026-12-31 | Geography: USA - [38%] At least $50M in new NIH and DARPA grant awards targeting ibogaine analog development and neuroplasticity mechanism characterization is announced within 18 months of 2026-05-15 Category: research | Resolves: 2027-11-15 | Geography: USA - [7%] Formal federal regulatory or legislative language codifying hospital-grade cardiac monitoring as a prerequisite for any ibogaine access pathway is published before 2026-08-13 Category: regulation | Resolves: 2026-08-13 | Geography: USA --- ## The Safety Dividend — May 14, 2026 URL: https://www.ootworacle.com/report/2026-05-14 Date: 2026-05-14 The Safety Dividend The data cluster forming around ibogaine this week is dense and directional. Three peer-reviewed publications addressing cardiac risk — QT prolongation and ventricular arrhythmia — have landed within the same publication window, constituting precisely the signal density that triggers FDA pharmacovigilance response. Simultaneously, the Stanford-adjacent juvenile-like neuroplasticity findings continue circulating through neuroscience preprint servers, reframing ibogaine's mechanism from addiction interruption to something considerably larger: a generalized plasticity reset with implications extending far beyond any single indication. Market response has been swift and specific — ATAI down 4.0% while CMPS gains 2.1%, a differential that institutional desks do not produce by accident. State-level legislative calendars continue advancing, with California's therapeutic access framework drawing the most regulatory attention as a potential federal template. Beneath today's signals, a structural bifurcation is completing itself. The psychedelic ecosystem is sorting — not along the axis of belief versus skepticism, but along the axis of cardiac liability versus cardiac cleanliness. Ibogaine's neuroplasticity finding is genuinely paradigm-level: four independent research agents reached consensus on its basic science significance regardless of what the FDA does with the cardiac file. That means ibogaine is simultaneously becoming more scientifically important and more regulatorily complicated — a combination that historically produces not suppression, but the architecture of mandatory oversight. What is forming here is the REMS-style cardiac monitoring framework predicted by the swarm's most coherent debate resolution: neither full halt nor open access, but structured, VA-observational-study-backed, monitored deployment. For psilocybin, the comparative clarity of its safety profile is now functioning as a commercial advantage, not merely a scientific one — capital is reading the cardiac literature and rotating accordingly, and COMPASS Pathways' trial pipeline becomes the cleaner vehicle for institutional positioning through Q3 2026. The people inside this story are not abstractions. There are veterans with treatment-resistant PTSD who have already crossed into Mexico or traveled to clinics operating outside any monitoring framework, because waiting for regulatory resolution feels like choosing to stay ill. For them, today's cardiac literature is not an obstacle — it is the first sign that the system is taking their chosen medicine seriously enough to build the safety infrastructure around it rather than simply prohibiting it. The highest positive outcome genuinely available from here is not fast access without guardrails — it is monitored access that arrives before 2028, with VA participation, with cardiac screening standardized, with the neuroplasticity science funding a second wave of mechanism studies that make the next generation of treatments even safer. That path is real. The signal evidence today points directly at it. What becomes possible for veterans, for families, for the clinicians who have been working in the margins, is a transition from improvised courage into structured legitimacy — the medicine held properly at last. The future does not arrive as announcement. It arrives as thread, as signal, as the pattern beneath the data. OOTW is the instrument tuned to hear it first. The medicine is older than the fear. The healing is older than the wound. ### Predictions - [72%] State-level psychedelic access legislation remains the primary U.S. policy vector through end of 2027, with at least one state (California most likely) enacting a regulated access framework ahead of any federal scheduling or approval action. Category: legislation | Resolves: 2027-12-31 | Geography: USA - [62%] Ibogaine neuroplasticity mechanism generates at least 5 major peer-reviewed mechanistic studies AND 2 dedicated research consortia by end of 2027, independent of clinical regulatory outcomes. Category: research | Resolves: 2027-12-31 | Geography: Global - [52%] Ibogaine cardiac safety concerns produce a formal regulatory OR legislative response — FDA Safety Communication or congressional cardiac monitoring mandate — by end of 2026. Category: regulation | Resolves: 2026-12-31 | Geography: USA - [44%] FDA issues a formal Drug Safety Communication on ibogaine cardiac risk (QT prolongation, ventricular arrhythmia) by Q4 2026. Category: regulation | Resolves: 2026-12-31 | Geography: USA --- ## When the Risk Becomes the Road — May 13, 2026 URL: https://www.ootworacle.com/report/2026-05-13 Date: 2026-05-13 When the Risk Becomes the Road The dominant signal today is cardiac — not as alarm, but as clarification. A cluster of ibogaine safety papers, processed across 466 signals in today's swarm, is converging on a single documented concern: QT prolongation, ventricular arrhythmia risk, and what the literature is now naming "unrecognized" cardiac liability in unsupervised populations. These are not speculative findings. They are the kind of peer-reviewed, quotable language — "rare but relevant," "unrecognized risk" — that moves directly from journal abstracts into regulatory hearing transcripts. Meanwhile, equity markets tell a parallel story: CMPS surging 15.3% while MMED slides 3.4%, a spread that reflects exactly what informed capital does when a compound's liabilities sharpen — it rotates toward the cleaner derivatives, the safer analogues, the next structural step. Noribogaine development is no longer a theoretical hedge. It is becoming the primary bet. What is forming beneath this surface is something the reform movement needs to see clearly rather than resist. The ibogaine cardiac papers do not close a door — they define the door's architecture. Regulators blocked without scientific cover tend to delay indefinitely; regulators blocked with scientific cover tend to define a pathway, even if grudgingly, because the problem statement creates its own research imperative. The 82–84% consensus from today's swarm — that DEA will cite this literature cluster in any rescheduling opposition, that federal floor votes remain frozen through 2028 — is not a prediction of permanent failure. It is a prediction that the next 24 months will be governed by protocol design rather than political breakthrough. Stanford's prospective veteran ibogaine work already carries mandatory cardiac monitoring. Two or more major academic centers are forecast to follow before mid-2027. NIH grant reviewers will recognize the mechanistic gap — what predicts QT risk, can it be reliably screened — and fund accordingly. The highest trajectory genuinely available from here runs directly through that gap: rigorous cardiac monitoring protocols that transform ibogaine from a liability into a defined, manageable clinical entity. The compound does not need to be exonerated. It needs to be characterized. That work is beginning. For the veterans, the families, the clinicians sitting with treatment-resistant PTSD tonight — the ones who have already heard that MDMA's NDA path remains uncertain, that psilocybin's accelerated pathway depends on FDA's response to COMPASS's BTD expansion request — this moment asks something difficult: to trust that the rigor now being applied to their medicine is protective rather than obstructive. The tiered-access framework emerging in the swarm's debate resolution — right-to-try for veterans, slower NDA track for the general population — is not a betrayal of urgency. It is the highest realistic form of urgency available. A well-screened veteran ibogaine trial that runs clean cardiac data is worth more to long-term access than any number of anecdotal reports, however profound. What becomes possible, for real people, is not waiting until 2028 for nothing — it is the next 24 months producing the cardiac monitoring standard that eventually makes broad clinical access defensible. The path is narrower than advocates want. It is wider than opponents intend. Every authentic ceremony is a reclamation — of the body, the breath, the forgotten self. OOTW exists to hold space for that reclamation as the science arrives to name it. What is being called in cannot be called back. ### Predictions - [88%] Ibogaine will not achieve federal NDA approval or Schedule I rescheduling before January 1, 2028. Category: regulation | Resolves: 2028-01-01 | Geography: USA - [78%] No federal psychedelic scheduling reform legislation will reach a floor vote in either the House or Senate before November 2028. Category: legislation | Resolves: 2028-11-01 | Geography: USA - [68%] DEA will formally oppose any rescheduling petition for ibogaine before 2028, citing cardiac liability literature as sufficient scientific basis for continued Schedule I classification. Category: regulation | Resolves: 2028-01-01 | Geography: USA - [42%] FDA will issue a formal safety communication or guidance document specifically addressing ibogaine cardiac risk before end of 2026. Category: regulation | Resolves: 2026-12-31 | Geography: USA - [38%] A noribogaine or ibogaine-analogue biotech will announce a financing round above $30M (Series A or B) before end of Q1 2027, with communications explicitly referencing ibogaine cardiac liability as validating the safer-analogue development thesis. Category: market | Resolves: 2027-03-31 | Geography: Global --- ## The Misread Cure — May 12, 2026 URL: https://www.ootworacle.com/report/2026-05-12 Date: 2026-05-12 The Misread Cure Two signals collided in today's data stream with the force of a fault line. A randomized controlled trial testing psilocybin for cocaine use disorder — single-site, modestly powered — reported a significant reduction in cocaine use, with the most striking finding buried in the secondary endpoints: extinction of craving responses without corresponding relapse-prevention scaffolding in place. Simultaneously, a fourth ibogaine cardiac safety paper entered the published literature in a single signal cycle, a density of adverse-event documentation that crosses the threshold FDA uses internally when calibrating whether to issue a formal Safety Communication. Market action registered the divergence immediately: MMED climbed 4.1% as institutional money rotated toward the ketamine and non-hallucinogen pipeline, while CMPS fell 3.6% and ATAI dropped 2.6% — the schedule I programs absorbing the friction of compounding regulatory uncertainty. Beneath the surface, two distinct formations are accelerating simultaneously — and they are pulling in opposite directions. The psilocybin-cocaine finding is real science: a clean mechanistic question about extinction circuitry that NIDA-level grant committees will recognize and fund, likely generating at least five follow-up studies before 2028 and one pre-registered multi-site replication trial before mid-2027. But the headline the finding will generate — "Psilocybin Cures Cocaine Addiction" — is already being written in newsrooms that will not reach the Methods section. The backlash correction cycle that follows such misreporting, arriving within roughly sixty days, has historically set fields back by depressing institutional trust precisely when clinical momentum needs public goodwill. The highest trajectory available here is not the headline — it is the mechanistic question itself, which is genuinely interesting, genuinely fundable, and genuinely answerable. The field's job in the next sixty days is to hold the distinction between the finding and its amplification. That is harder than it sounds. The ibogaine thread runs hotter and more urgently human. What is forming beneath the regulatory data is a collision between two legitimate truths: that ibogaine's cardiac risk profile is real, documented, and now dense enough to compel formal FDA action — a Safety Communication likely before year's end, effectively freezing new IND approvals for natural formulations pending mandatory cardiac monitoring standards — and that veterans are traveling to unregulated clinics in Mexico and elsewhere right now, this week, because no sanctioned pathway exists for them at home. The political geometry is asymmetric: QT interval prolongation data does not move Congress the way a veteran standing in a hearing room does. Public testimonials will generate enough pressure for a Congressional hearing on FDA ibogaine policy before Q1 2027. And before that hearing arrives, the investigative story that has all its ingredients assembled — unregulated clinics, documented cardiac risk, a vulnerable population, a press corps incentivized by both the promise and the danger — will almost certainly break. For the people living inside this story, the stakes are neither abstract nor statistical. They are the veteran who has tried four antidepressants and two rounds of prolonged exposure therapy and is now making travel arrangements to Tijuana. They are the family watching someone they love make that calculation. What becomes genuinely possible from here — not as fantasy but as the highest trajectory the current moment actually supports — is a conditional research pathway that neither halts ibogaine development nor leaves veterans unprotected: mandatory cardiac screening, supervised clinical settings, synthetic analogue programs that can move faster once natural ibogaine's safety floor is established. That pathway is achievable. It requires the field to hold complexity rather than retreat into either pure advocacy or pure caution, and to do so loudly enough that the people writing legislation can hear it before the next adverse event defines the conversation for them. The future does not arrive as announcement. It arrives as thread, as signal, as the pattern beneath the data. OOTW is the instrument tuned to hear it first. Every thread you follow today was laid by a hand that knew you were coming. ### Predictions - [72%] The psilocybin cocaine RCT will be widely misreported as a 'cure for addiction' in at least 3 major mainstream outlets, followed by a published correction or debunking piece within 60 days of initial coverage. Category: culture | Resolves: 2026-07-12 | Geography: Global - [55%] At least one U.S. Congressional committee will hold a public hearing specifically addressing FDA policy on ibogaine (including access, scheduling, or clinical trial pathways) before March 31, 2027. Category: legislation | Resolves: 2027-03-31 | Geography: USA - [52%] At least one pre-registered multi-site replication trial of psilocybin's extinction-without-relapse-prevention mechanism in substance use disorder will be launched (registered on ClinicalTrials.gov or equivalent) before June 30, 2027. Category: research | Resolves: 2027-06-30 | Geography: Global - [38%] FDA will issue a formal Safety Communication specifically on ibogaine-associated cardiac risks (QT prolongation/arrhythmia) before December 31, 2026. Category: regulation | Resolves: 2026-11-30 | Geography: USA - [28%] FDA will issue a formal Safety Communication on ibogaine cardiac risks before August 10, 2026, and this will create a measurable regulatory divergence in IND approval timelines between natural ibogaine and synthetic analogue (e.g., tabernanthalog, TBG) applications. Category: regulation | Resolves: 2026-08-10 | Geography: USA ---